Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

PureTech (PRTC) Share Price

Price 110.00p on 01-04-2026 at 18:50:09
Change 2.00p 1.85%
Buy 110.00p
Sell 109.60p
Last Trade: Unknown 15,000.00 at 110.00p
Day's Volume: 1,277,081
Last Close: 110.00p
Open: 113.00p
ISIN: GB00BY2Z0H74
Day's Range 109.40p - 113.00p
52wk Range: 100.40p - 148.00p
Market Capitalisation: £265.99m
VWAP: 110.06465p
Shares in Issue: 241.81m

PureTech (PRTC) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 15,000 110.00p OTC Trade
17:08:56 - 01-Apr-26
Unknown* 208,077 110.00p Uncrossing Trade
16:35:20 - 01-Apr-26
Buy* 21 110.00p Automatic Execution
16:29:55 - 01-Apr-26
Buy* 50 110.00p Automatic Execution
16:29:44 - 01-Apr-26
Buy* 714 110.00p Automatic Execution
16:29:23 - 01-Apr-26
Buy* 889 110.00p Automatic Execution
16:29:23 - 01-Apr-26
Buy* 407 110.00p Automatic Execution
16:29:23 - 01-Apr-26
Buy* 81 110.00p Automatic Execution
16:29:23 - 01-Apr-26
Buy* 134 110.00p Automatic Execution
16:29:16 - 01-Apr-26
Buy* 20 110.00p Automatic Execution
16:29:16 - 01-Apr-26
See more PureTech trades

PureTech (PRTC) Share Price History

Time period:
to
Date Open High Low Close Volume
1st Apr 2026 (Wed) 113.00 113.00 109.40 110.00 1,277,081
31st Mar 2026 (Tue) 107.80 109.20 107.40 108.00 940,746
30th Mar 2026 (Mon) 116.20 116.20 108.00 108.00 799,681
27th Mar 2026 (Fri) 118.20 118.20 110.00 110.00 686,172
26th Mar 2026 (Thu) 115.00 115.60 113.40 114.60 293,260
25th Mar 2026 (Wed) 120.00 120.00 114.00 115.00 299,041
24th Mar 2026 (Tue) 114.00 115.20 112.40 114.20 235,278
23rd Mar 2026 (Mon) 116.00 117.40 110.80 114.00 440,265
20th Mar 2026 (Fri) 119.00 119.00 115.60 115.60 423,659
19th Mar 2026 (Thu) 118.00 118.40 115.00 117.20 357,049
18th Mar 2026 (Wed) 120.20 123.80 118.40 118.40 465,726
17th Mar 2026 (Tue) 120.60 121.80 119.20 120.80 454,813
16th Mar 2026 (Mon) 120.40 121.00 118.20 120.00 331,694
13th Mar 2026 (Fri) 123.00 123.40 121.00 121.20 168,339
12th Mar 2026 (Thu) 124.80 125.20 122.60 123.20 190,505
11th Mar 2026 (Wed) 125.00 125.60 123.40 125.20 258,623
10th Mar 2026 (Tue) 123.40 125.60 123.40 125.20 198,057
9th Mar 2026 (Mon) 123.20 123.20 120.60 122.20 262,638
6th Mar 2026 (Fri) 125.20 125.20 122.00 123.60 211,846
5th Mar 2026 (Thu) 125.00 128.20 124.20 124.60 468,983
4th Mar 2026 (Wed) 125.00 126.20 122.20 125.60 418,321
3rd Mar 2026 (Tue) 124.80 124.80 120.60 123.60 459,127
2nd Mar 2026 (Mon) 125.80 125.80 119.40 124.40 463,078
See more PureTech price history

PureTech (PRTC) Regulatory News

Date Source Headline
1st Apr 2026 7:00 am RNS Total Voting Rights
25th Mar 2026 6:00 pm RNS-R PRTC’s Seaport: GlyphAllo Paper Published
13th Mar 2026 4:35 pm RNS PDMR Notification RSU Vesting
2nd Mar 2026 7:00 am RNS Total Voting Rights
25th Feb 2026 7:00 am RNS-R PRTC to Present at Leerink Healthcare Conference
19th Feb 2026 5:15 pm RNS-R PRTC's Deupirfenidone Granted FDA & EU ODD for IPF
6th Jan 2026 12:00 pm RNS-R PureTech to Present at the JP Morgan Conference
18th Dec 2025 7:00 am RNS PureTech Appoints Robert Lyne as CEO
10th Dec 2025 5:41 pm RNS Results of AGM on June 16, 2025 – Update Statement
10th Dec 2025 5:30 pm RNS Holding(s) in Company
See more PureTech regulatory news

PureTech (PRTC) Share News

PureTech says its pulmonary fibrosis drug granted orphan designation

20th Feb 2026 13:11

(Alliance News) - PureTech Health PLC said on Friday its drug treating idiopathic pulmonary fibrosis, deupirfenidone, has been designated as an orphan drug by both the US Food & Drug Administration and the European Commission. Read More

IN BRIEF: PureTech Health promotes interim CEO Robert Lyne to CEO

18th Dec 2025 11:11

PureTech Health PLC - Boston, Massachusetts-based biotech and pharmaceutical firm - Promotes interim Chief Executive Officer Robert Lyne to CEO on a permanent basis from Thursday. Lyne has served as interim CEO since July, having joined the company in January 2024 as chief portfolio officer. He has overseen progress across PureTech's programmes and advancing strategic and operational priorities. Lyne was previously CEO of Arix Bioscience PLC. Read More

FDA backs PureTech's phase 3 move for IPF drug deupirfenidone

8th Dec 2025 12:34

(Alliance News) - PureTech Health PLC on Monday said its idiopathic pulmonary fibrosis drug candidate deupirfenidone has cleared a key regulatory milestone, with the US Food & Drug Administration backing progression into a pivotal phase 3 trial planned for the first half of 2026. Read More

SMALL-CAP WINNERS: Mears rises as annual profit set to beat forecasts

8th Dec 2025 10:59

(Alliance News) - The following stocks are the leading risers among London Main Market small-caps on Monday. Read More

TRADING UPDATES: London BTC continues work towards Nasdaq listing

5th Dec 2025 21:58

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More

See more PureTech news
FTSE 100 Latest
Value10,364.79
Change188.34

Login to your account

Forgot Password?

Not Registered